Ionizable Lipid Compound for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid compounds for nucleic acid delivery face challenges such as low efficiency, high toxicity, and poor targeting, making it difficult to effectively deliver mRNA and pDNA into cells.
Innovation Solution
A new lipid compound with a branched chain structure that ionizes under acidic conditions, forming lipid nanoparticles capable of binding to nucleic acids and facilitating their delivery through electrostatic interactions, while maintaining electrical neutrality under neutral conditions to reduce cytotoxicity and enhance stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional lipid compounds are used for nucleic acid delivery, then delivery capability is provided, but transfection efficiency is low and toxicity is high
Solution Approach 1:
The patent modifies the chemical structure of lipid compounds by introducing specific functional groups (carboxyl, hydroxyl, amino groups) and controlling chain lengths (C12-C22) to optimize the balance between transfection efficiency and toxicity. The structural parameters including head group type, chain length, and functional group positioning are systematically adjusted to achieve low toxicity while maintaining high delivery capability.
Solution Approach 2:
The patent creates composite lipid structures combining hydrophilic head groups with hydrophobic tails, integrating multiple functional groups (carboxyl, hydroxyl, amino) within a single molecule. This composite structure enables simultaneous achievement of solubility, membrane interaction, and low toxicity, resolving the contradiction between delivery efficiency and harmful effects.
2Productivity
If lipid compounds with high delivery efficiency are used, then nucleic acid delivery is improved, but stability and pharmacokinetic characteristics deteriorate
Solution Approach 1:
The patent optimizes structural parameters including hydrocarbon chain length (C12-C22), head group composition, and functional group types to achieve the right balance between delivery efficiency and stability. The specific structural modifications enhance both the delivery capability and the pharmacokinetic stability of the lipid compounds.
3Ease of operation
If mRNA is delivered without a delivery system, then simplicity is maintained, but cell membrane penetration is impossible due to large size and negative charge
Solution Approach 1:
The patent introduces lipid compounds as intermediary carriers that mediate between mRNA and cell membranes. These lipid compounds form complexes with mRNA, enabling the negatively charged, large-sized mRNA to overcome the cell membrane barrier through the lipid mediator's amphiphilic structure and membrane interaction capabilities.
4Productivity
If viral vectors are used for nucleic acid delivery, then transfection efficiency is high, but safety and targeting are poor
Solution Approach 1:
The patent employs non-viral lipid compounds as temporary, disposable delivery vehicles that perform their function and are then metabolized without causing long-term safety issues. Unlike viral vectors that integrate into the genome and cause persistent safety concerns, these lipid compounds are short-lived and safely eliminated after delivery, achieving high efficiency without compromising safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid compound achieves efficient transfection of mRNA and pDNA, comparable to commercial transfection reagents, with improved stability and pharmacokinetic characteristics, reducing toxicity and enhancing delivery efficiency.
Implementation Method 1
Ionizable lipid protonates the amine head at acidic pH to obtain a positive charge, which can promote the binding of positively charged lipids to negatively charged mRNA through electrostatic interaction.
Implementation Method 2
Ionizable lipids in vivo are electrically neutral during transportation, resulting in low biological toxicity. An ionizable lipid is an amphiphilic structure with a hydrophilic head, which contains one or more ionizable amines and multiple hydrophobic alkane chains that promote self-assembly.
Implementation Method 3
When lipid nanoparticles (LNP) are transported in the intracellular environment, the acidic microenvironment can interact with the positively charged lipid and the ionic inner membrane, promoting membrane fusion and instability, thereby releasing mRNA from LNPs into the cytoplasm.
Data Source
AI summary
A lipid compound and a preparation method therefor, and a use thereof are provided. The lipid compound is safe, efficient and ionizable and the structure of the lipid compound is divided into a hydrophilic amino group, a linking group, and a hydrophobic alkyl group. The preparation method of the lipid compound is simple, green and efficient. The lipid compound can be widely used in preparation of a drug carrier.